Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia

rifosine plus bortezomib, there were 2 PR's and 1 MR. Two additional MR's were observed on this combination after dexamethasone was added; both of these patients were previously refractory to the combination of bortezomib + dexamethasone without perifosine. Eleven patients remain on study and the phase II portion of the study is now open and enrolling.

A second poster presented by Dr. Richardson, entitled " Perifosine (KRX- 0401) + Low Dose Dexamethasone is Active in Patients with Relapsed and Refractory Multiple Myeloma (MM): Perifosine MM Investigator Group Phase II Multicenter Study Update" demonstrated that 78% of patients treated with perifosine plus low dose dexamethasone had at least stable disease (SD), including 26% that had a PR or MR. Patients continue on study now ranging from 6 months up through 1 year.

Dr. Andrzej Jakubowiak, Director of the myeloma program at the University of Michigan Cancer Center, presented a poster entitled "A Multicenter Phase I Trial of Perifosine (KRX-0401) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: Preliminary Results. Multiple Myeloma Research Consortium (MMRC) Trial", demonstrating early encouraging results, with 50% of patients achieving a partial response or better.

Commenting on the data, Dr. Richardson stated, "Perifosine's potential in combination with bortezomib, dexamethasone and other novel therapies to overcome drug-resistant multiple myeloma is promising. Our team of investigators, including top centers across the country and now incorporating the considerable resources of the MMRC for one of the trials, is committed to completing enrollment in our studies and evaluating future clinical strategies to improve patient outcome."

Perifosine in the treatment of Patients with Relapsed/Refractory Waldenstrom's Macroglobulinemia:

A poster entitled "A Phase II Trial of Perifosine (KRX-0401) in Relapsed and/or Refractory Wald
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
2. AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results for Anti-Cancer Compound Perifosine at ASCO Meeting
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:12/24/2014)... Dec. 23, 2014  Lockton Dunning Benefits, the ... Companies, announced the addition of Vice President ... Lockton Dunning,s Pharmacy Consulting team, Excelsior Solutions. ... industry experience to the position.  Most recently, she ... at Diplomat Specialty Pharmacy, where she has held ...
(Date:12/24/2014)... -- In response to urgent requests from the Deputy Minister of ... , Direct Relief delivered two 10-bed medical tents to ... local health workers who contract Ebola while fighting the outbreak. ... was constructed for foreign health care workers who may contract ... Sierra Leonean health workers. With Sierra ...
(Date:12/22/2014)... JUNCTION, N.J. , Dec. 22, 2014 /PRNewswire/ ... company marketing its CytoSorb® blood purification technology to ... surgery patients in 28 countries worldwide, today announced ... Russo , MD, FACS, as its Senior Vice ... Dr. Di Russo ...
Breaking Medicine Technology:Kim Foerster Joins Lockton Companies 2First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5
... RALEIGH, N.C., Nov. 15, 2010 PRA International, a ... experts will lead a panel at the 9th annual ... 17-18 November 2010. PRA, a co-sponsor of the conference, ... Stansfield, Executive Vice President of PRA,s Product Registration group ...
... 2010 The Radiology journal released new ... women with newly diagnosed breast cancer that shows Positron ... study found that PEM was significantly more precise at ... "Positive Predictive Value" or "PPV," therefore reducing the number ...
Cached Medicine Technology:PRA International Expert to Chair Panel at Partnerships Conference 2Radiology Journal Publishes Data That PEM Scanners May Reduce Unnecessary Breast Biopsies and Offer an Alternative for Women Who Cannot Tolerate MRI 2
(Date:12/25/2014)... Dennis Thompson HealthDay ... Very sick children with complex chronic illnesses can receive effective, ... "medical home," with easy access to a team of dedicated ... less likely to become seriously ill and need either hospitalization ... treatment at an enhanced medical home clinic at the University ...
(Date:12/25/2014)... common during the holidays, but there are strategies that can ... arrive at a party hungry. It may seem logical to ... party, but deprivation leads to hunger, and hunger leads to ... Mount Kisco, N.Y., said in a hospital news release. ... to have a snack before attending a party when you ...
(Date:12/25/2014)... By Dennis Thompson ... -- Researchers could be closing in on a "fountain of ... improve the health of older adults, a new study suggests. ... when given a drug that targets a genetic signaling pathway ... maker Novartis report. The experimental medication, a ...
(Date:12/25/2014)... New York (PRWEB) December 25, 2014 ... continue to move forward in a number of multidistrict ... of West Virginia, Bernstein Liebhard LLP reports. According to ... is scheduled to convene a Joint Status Conference in ... 10:00 a.m. Parties have been directed to submit a ...
(Date:12/25/2014)... 2014 Plugin creators from Pixel Film ... fully customizable business presentation tool made specifically for ... 5k business tool, users can now display their stats ... Pixel Film Studios. “ProFire 5k gives users a multiple ... professionalism to a presentation” , Pixel Film Studios takes ...
Breaking Medicine News(10 mins):Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2
... Smithsonian Whistleblower and Asbestos Experts to Dispute Smithsonian,s ... Safe for Workers and Public WASHINGTON, March 16 ... press conference on Tuesday, March 17, to announce ... the U.S. Office of Special Counsel. In ...
... Inc. (NYSE: WLP ) has placed No. ... Diversity(R) list, which was announced last week by DiversityInc.A ... from last year, vied for the honor this year, ... companies. "In its fourth year participating, WellPoint demonstrates the ...
... Children,s National Medical Center and colleagues in Tokyo publish results, video ... , ... Washington, DC (PRWEB) March 16, 2009 -- Genetic ... Center of Neurology and Psychiatry in Tokyo published the results of ...
... maintain a healthy weight and who have lower perceived ... associated with aging than obese and stressed women, according ... Sister Study. The long-term Sister Study is looking at ... had breast cancer to identify factors associated with developing ...
... Uninsured, including those who are recently unemployed, can attend ... expertPITTSBURGH, March 16 As the nation marks National ... Highmark is offering resources to help Pennsylvanians without health ... the Pennsylvania Insurance Department found that the uninsured ranks ...
... key, however, experts say, , , MONDAY, March 16 (HealthDay ... and tools have significantly improved the management of this ... in the mid-,90s, children with severe asthma during 2004 ... and rescue inhalers, and their lung function scores were ...
Cached Medicine News:Health News:Smithsonian Worker Exposed to Asbestos Files Whistleblower Retaliation Complaint 2Health News:WellPoint Named to DiversityInc's '2009 DiversityInc Top 50 Companies for Diversity'(R) 2Health News:WellPoint Named to DiversityInc's '2009 DiversityInc Top 50 Companies for Diversity'(R) 3Health News:WellPoint Named to DiversityInc's '2009 DiversityInc Top 50 Companies for Diversity'(R) 4Health News:First Treatment for Muscular Dystrophy in Sight: Scientists Harness Exon-Skipping in Large Animal to Successfully Treat Duchenne Muscular Dystrophy 2Health News:First Treatment for Muscular Dystrophy in Sight: Scientists Harness Exon-Skipping in Large Animal to Successfully Treat Duchenne Muscular Dystrophy 3Health News:First Treatment for Muscular Dystrophy in Sight: Scientists Harness Exon-Skipping in Large Animal to Successfully Treat Duchenne Muscular Dystrophy 4Health News:First Treatment for Muscular Dystrophy in Sight: Scientists Harness Exon-Skipping in Large Animal to Successfully Treat Duchenne Muscular Dystrophy 5Health News:First sister study results reinforce the importance of healthy living 2Health News:First sister study results reinforce the importance of healthy living 3Health News:Highmark Offers Resources to Help Pennsylvanians Without Health Insurance During Cover the Uninsured Week 2Health News:Highmark Offers Resources to Help Pennsylvanians Without Health Insurance During Cover the Uninsured Week 3Health News:New Treatments Improve Control for Severe Asthma 2Health News:New Treatments Improve Control for Severe Asthma 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: